Leukocare Overview

  • Founded
  • 2003

Founded

  • Status
  • Private

  • Employees
  • 77

Employees

  • Latest Deal Type
  • PE Growth

  • Financing Rounds
  • 7

Leukocare General Information

Description

Developer of protein stabilizing technologies intended for a reduction in systemic inflammation in patients during cardiac surgery. The company offers formulation technologies through the application of bioinformatics and artificial intelligence for biopharmaceuticals, viral vectors and vaccines as well as biofunctionalized devices, enabling patients to avail a reduced leukocyte activity in an extracorporeal blood circuit employing an antibody.

Contact Information

Website
www.leukocare.com
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Other Devices and Supplies
Primary Office
  • Am Klopferspitz 19a
  • 82152 Munich
  • Germany
+49 089 00000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Leukocare Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Leukocare‘s full profile, request access.

Request a free trial

Leukocare Patents

  • 93

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 12

    Granted

  • 4

    Pending

  • 000

    Expiring in next 12 mo

Leukocare Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4097145-A1 Reduction of adsorption Pending 30-Jan-2020 000000000
US-20230041240-A1 Reduction of adsorption Pending 30-Jan-2020 000000000
EP-4013436-A1 Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy Pending 14-Aug-2019 00000000
US-20220325250-A1 Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy Pending 14-Aug-2019 00000000
US-20220202717-A1 Novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy Pending 16-Sep-2016 C12N7/00 0
To view Leukocare’s complete patent history, request access »

Leukocare Executive Team (7)

Name Title Board Seat Contact Info
Michael Scholl Chief Executive Officer & Co-Founder
Georg Dönges Ph.D Chief Financial Officer
Cornelius Pompe Ph.D Chief Development Officer
Dirk Winnemöller Chief Business Officer
Gerhard Ries Ph.D Member of Supervisory Board
You’re viewing 5 of 7 executive team members. Get the full list »

Leukocare Board Members (8)

Name Representing Role Since
0000000 0000000 00 Self Supervisory Board Member 000 0000
0000000 00000 Self Chairman of Scientific Advisory Board 000 0000
000000 000000 00.0 Leukocare Chairman of the Supervisory Board 000 0000
0000-0000 0000000 Self Supervisory Board Member 000 0000
0000 000000 Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Leukocare Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Leukocare Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Leukocare‘s full profile, request access.

Request a free trial